Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre.

Besada E, Koldingsnes W, Nossent JC.

Rheumatology (Oxford). 2013 Nov;52(11):2041-7. doi: 10.1093/rheumatology/ket257. Epub 2013 Aug 11.

2.

Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis.

Besada E, Koldingsnes W, Nossent JC.

Rheumatology (Oxford). 2014 Oct;53(10):1818-24. doi: 10.1093/rheumatology/keu194. Epub 2014 May 15.

3.

Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.

Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sánchez-Menéndez M, Ytterberg SR, Fervenza FC, Specks U.

Arthritis Rheum. 2012 Nov;64(11):3770-8. doi: 10.1002/art.34584.

4.

Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.

Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, Noelle B, Reinhold-Keller E, Gross WL.

Ann Rheum Dis. 2012 Mar;71(3):327-33. doi: 10.1136/ard.2011.153601. Epub 2011 Oct 21.

PMID:
22021864
5.

Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.

Calich AL, Puéchal X, Pugnet G, London J, Terrier B, Charles P, Mouthon L, Guillevin L; French Vasculitis Study Group.

J Autoimmun. 2014 May;50:135-41. doi: 10.1016/j.jaut.2014.03.002. Epub 2014 Apr 2.

PMID:
24703438
6.

Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.

Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A, Smith KG, Jayne DR.

Rheumatology (Oxford). 2015 Jul;54(7):1153-60. doi: 10.1093/rheumatology/keu452. Epub 2014 Dec 3.

7.

Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis.

Roubaud-Baudron C, Pagnoux C, Méaux-Ruault N, Grasland A, Zoulim A, LE Guen J, Prud'homme A, Bienvenu B, de Menthon M, Camps S, LE Guern V, Aouba A, Cohen P, Mouthon L, Guillevin L; French Vasculitis Study Group.

J Rheumatol. 2012 Jan;39(1):125-30. doi: 10.3899/jrheum.110143. Epub 2011 Nov 15.

PMID:
22089465
8.
9.

Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).

Thiel J, Hässler F, Salzer U, Voll RE, Venhoff N.

Arthritis Res Ther. 2013 Sep 24;15(5):R133. doi: 10.1186/ar4313.

10.

Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis: Impact on Localized and Nonlocalized Disease.

Joshi L, Tanna A, McAdoo SP, Medjeral-Thomas N, Taylor SR, Sandhu G, Tarzi RM, Pusey CD, Lightman S.

Ophthalmology. 2015 Jun;122(6):1262-8. doi: 10.1016/j.ophtha.2015.01.016. Epub 2015 Mar 4.

PMID:
25745876
11.
12.

Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.

Charles P, Néel A, Tieulié N, Hot A, Pugnet G, Decaux O, Marie I, Khellaf M, Kahn JE, Karras A, Ziza JM, Deligny C, Tchérakian C, Guillevin L; French Vasculitis Study Group.

Rheumatology (Oxford). 2014 Mar;53(3):532-9. doi: 10.1093/rheumatology/ket381. Epub 2013 Nov 26.

13.

Rituximab (MABTHERA) and severe polyangiitis. An option for patients informed of the uncertainties.

[No authors listed]

Prescrire Int. 2015 Jun;24(161):145-8. Review.

PMID:
26436161
14.

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.

Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Viviano L, Ding L, Sejismundo LP, Mieras K, Iklé D, Jepson B, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.

Arthritis Rheum. 2013 Sep;65(9):2441-9. doi: 10.1002/art.38044.

15.

Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience.

Hart PA, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, Levy MJ, Pearson RK, Petersen BT, Smyrk TC, Sugumar A, Takahashi N, Vege SS, Chari ST.

Gut. 2013 Nov;62(11):1607-15. doi: 10.1136/gutjnl-2012-302886. Epub 2012 Aug 30.

PMID:
22936672
16.

Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.

Reguiai Z, Tabary T, Maizières M, Bernard P.

J Am Acad Dermatol. 2012 Oct;67(4):623-9. doi: 10.1016/j.jaad.2011.12.019. Epub 2012 Jan 20.

PMID:
22261417
17.

Lower doses of rituximab in remission induction for refractory granulomatosis with polyangiitis.

Wawrzycka-Adamczyk K, Zugaj A, Włudarczyk A, Kosałka J, Sznajd J, Bazan-Socha S, Musiał J.

Przegl Lek. 2014;71(12):663-5.

PMID:
25951692
18.

Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.

Timlin H, Lee SM, Manno RL, Seo P, Geetha D.

Semin Arthritis Rheum. 2015 Aug;45(1):67-9. doi: 10.1016/j.semarthrit.2015.02.005. Epub 2015 Feb 20.

19.

Wegener granulomatosis (granulomatosis with polyangiitis): evolving concepts in treatment.

Lynch JP 3rd, Tazelaar H.

Semin Respir Crit Care Med. 2011 Jun;32(3):274-97. doi: 10.1055/s-0031-1279825. Epub 2011 Jun 14.

PMID:
21674414
20.

Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.

Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D.

Rheumatology (Oxford). 2006 Nov;45(11):1432-6. Epub 2006 Apr 21.

Items per page

Supplemental Content

Write to the Help Desk